Genetic associations with a fever after measles-containing vaccines

References

• Launey Y, Nesseler N, Malledant Y, Seguin P. Clinical review: fever in septic ICU patients–friend or foe? Crit Care. 2011;15:222.
   PubMed Web of Science ®Google Scholar
• Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15:335–49.
   PubMed Web of Science ®Google Scholar
• Wilson K, Hawken S, Kwong JC, Deeks S, Crowcroft NS, Van Walraven C, Potter BK, Chakraborty P, Keelan J, Pluscauskas M, et al. Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis. PLoS One. 2011;6:e27897. doi:10.1371/journal.pone.0027897.
   PubMed Web of Science ®Google Scholar
• Saada A, Lieu TA, Morain SR, Zikmund-Fisher BJ, Wittenberg E. Parents’ choices and rationales for alternative vaccination schedules: a qualitative study. Clin Pediatr (Phila). 2014;54(3):236–43.
   PubMed Web of Science ®Google Scholar
• Williams SE. What are the factors that contribute to parental vaccine-hesitancy and what can we do about it? Hum Vaccin Immunother. 2014;10:2584–96. doi:10.4161/hv.28596.
   PubMed Web of Science ®Google Scholar
• Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak - california, december 2014-february 2015. MMWR Morb Mortal Wkly Rep. 2015;64:153–54.
   PubMed Web of Science ®Google Scholar
• McDonald R, Ruppert PS, Souto M, Johns DE, McKay K, Bessette N, McNulty LX, Crawford JE, Bryant P, Mosquera MC, et al. Notes from the field: measles outbreaks from imported cases in orthodox Jewish communities - New York and New Jersey, 2018–2019. MMWR Morb Mortal Wkly Rep. 2019;68:444–45. doi:10.15585/mmwr.mm6819a4.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, Belongia EA, Yih WK, Nordin JD, Hechter RC, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015;135:e321–9. doi:10.1542/peds.2014-1822.
   PubMed Web of Science ®Google Scholar
• Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles Vaccine. In: Plotkin SA, Orenstein W, Offit PA, editors. Vaccines. (Basel): Saunders Elsevier; 2008. p. 353–98.
   Google Scholar
• Hirayama M. Measles vaccines used in Japan. Rev Infect Dis. 1983;5:495–503. doi:10.1093/clinids/5.3.495.
   PubMedGoogle Scholar
• Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet. 1986;1:939–42.
   PubMed Web of Science ®Google Scholar
• Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012;31:e133–40. doi:10.1097/INF.0b013e318259fc8a.
   PubMed Web of Science ®Google Scholar
• Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, Baxter R, Hambidge S, Nordin J, Naleway A, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126:e1–8. doi:10.1542/peds.2010-0665.
   PubMed Web of Science ®Google Scholar
• Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012;30:3929–36. doi:10.1016/j.vaccine.2012.03.080.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013;167:1111–17. doi:10.1001/jamapediatrics.2013.2745.
   PubMed Web of Science ®Google Scholar
• Group MS. Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Hum Vaccin Immunother. 2018;14:2921–31.
   PubMed Web of Science ®Google Scholar
• Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, Huang F, Eitson JL, Hollegaard MV, Svanström H, Vestergaard M, et al. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet. 2014;46:1274–82. doi:10.1038/ng.3129.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, McDonald J, Fireman B, Naleway A, Glanz J, Jackson LA, Donahue JG, Jacobsen SJ, Weintraub E, et al. Risk factors and familial clustering for fever 7–10days after the first dose of measles vaccines. Vaccine. 2017;35:1615–21. doi:10.1016/j.vaccine.2017.02.013.
   PubMed Web of Science ®Google Scholar
• Zerbo O, Glanternik JR, Modaressi S, Goddard K, Ross P, Lewis N, Klein NP. Parental risk factors for fever in their children 7–10 days after the first dose of measles-containing vaccines. Hum Vaccin Immunother. 2019;16(4):875–80.
   Web of Science ®Google Scholar
• Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2:205–14. doi:10.4161/hv.2.5.3246.
   PubMed Web of Science ®Google Scholar
• Brunell PA, Weigle K, Murphy MD, Shehab Z, Cobb E. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA. 1983;250:1409–12. doi:10.1001/jama.1983.03340110023025.
   PubMed Web of Science ®Google Scholar
• Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. Twin studies of immunogenicity–determining the genetic contribution to vaccine failure. Vaccine. 2001;19:2434–39. doi:10.1016/S0264-410X(00)00468-0.
   PubMed Web of Science ®Google Scholar
• Schaid DJ, Haralambieva IH, Larrabee BR, Ovsyannikova IG, Kennedy RB, Poland GA. Heritability of vaccine-induced measles neutralizing antibody titers. Vaccine. 2017;35:1390–94. doi:10.1016/j.vaccine.2017.01.078.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis. 2006;193:655–63. doi:10.1086/500144.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine. 2007;25:3090–100. doi:10.1016/j.vaccine.2007.01.020.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine. 2012;30:2146–52. doi:10.1016/j.vaccine.2012.01.038.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Schaid DJ, Larrabee BR, Haralambieva IH, Kennedy RB, Poland GA. A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses. PLoS One. 2017;12:e0171261. doi:10.1371/journal.pone.0171261.
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013;12:57–70.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms. Hum Hered. 2011;72:206–23. doi:10.1159/000331585.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Poland GA, Cunningham JM, Jacobson RM, Ovsyannikova IG, Vierkant RA, Wu Y, Pankratz VS. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol. 2007;120:666–72. doi:10.1016/j.jaci.2007.04.036.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Pankratz VS, Jacobson RM, Poland GA. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine. 2008;26:1731–36. doi:10.1016/j.vaccine.2008.01.017.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Richmond P, Khoo SK, Zhang G, Yerkovich ST, Le Souef PN, Hayden CM. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine. 2011;29:5407–13. doi:10.1016/j.vaccine.2011.05.068.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Hayden CM, Khoo SK, Zhang G, Le Souef PN, Richmond P. CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. Clin Vaccine Immunol. 2012;19:704–10.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Yerkovich ST, Khoo SK, Zhang G, Upham J, Le Souef PN, Richmond P, Hayden CM. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics. 2012;64:219–28. doi:10.1007/s00251-011-0574-0.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Yerkovich ST, Khoo SK, Zhang G, Upham J, Le Souef PN, Richmond P, Hayden CM. TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum Immunol. 2012;73:677–85. doi:10.1016/j.humimm.2012.03.004.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Hayden CM, Khoo SK, Naniche D, Mandomando IM, Zhang G, Richmond P, Le Souëf PN. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine. 2012;30:6180–85. doi:10.1016/j.vaccine.2012.07.063.
   PubMed Web of Science ®Google Scholar
• [accessed 2019 Nov 8].https://bioinformatics.bethematchclinical.org/hla-resources/haplotype-frequencies/high-resolution-hla-alleles-and-haplotypes-in-the-us-population/.
   Google Scholar
• Mayo O. A century of Hardy-Weinberg equilibrium. Twin Res Hum Genet. 2008;11:249–56. doi:10.1375/twin.11.3.249.
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–22. doi:10.1016/S0140-6736(02)08158-8.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32. doi:10.1016/S0140-6736(02)07873-X.
   PubMed Web of Science ®Google Scholar
• Symonds W, Cutrell A, Edwards M, Steel H, Spreen B, Powell G, McGuirk S, Hetherington S. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565–73. doi:10.1016/S0149-2918(02)85132-3.
   PubMed Web of Science ®Google Scholar
• Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, Scott TR. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38:2171–72. doi:10.1345/aph.1E202.
   PubMed Web of Science ®Google Scholar
• Dunstan SJ, Hue NT, Han B, Li Z, Tram TT, Sim KS, Parry CM, Chinh NT, Vinh H, Lan NPH, et al. Variation at HLA-DRB1 is associated with resistance to enteric fever. Nat Genet. 2014;46:1333–36. doi:10.1038/ng.3143.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. Vaccine. 2017;35:1926–35. doi:10.1016/j.vaccine.2017.02.035.
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill DE, Schaid DJ, Poland GA. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. Hum Genet. 2017;136:421–35. doi:10.1007/s00439-017-1768-9.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–85. doi:10.1038/nature09907.
   PubMed Web of Science ®Google Scholar